Shionogi Signs a Research Collaboration with UBE Industries for the Development of Anti-RS Virus Drug Candidates
Shots:
- Shionogi and UBE Industries collaborates for development of anti-RS (respiratory syncytial) virus drugs to treat Respiratory Syncytial Virus (RSV) infection
- The focus of the agreement is to combine Shionogi’s drug discovery platform with UBE’s drug design technology for SAR (Structure-Activity Relationship) study
- UBE Industries’ Drug discovery platform uses polymer synthesis technology for the development of drug candidates in multiple therapeutic area
Ref: Shionogi | Image: Japan Products
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com